Women in England will be able to obtain the contraceptive pill directly from their local pharmacy without requiring a GP referral as of next month.
To access the service, women can visit participating pharmacies for a confidential consultation with a pharmacist, who can make shared decisions with the person regarding their initial or ongoing supply of the contraceptive pill. For combined oral hormonal contraception, body mass index (BMI) and blood pressure measurements will be taken during the consultation.
This NHS announcement comes over two years after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) allowed two brands, Hana and Lovima, to be made available over the counter without a prescription. These contraceptive pills contained synthetic progesterone. The latest announcement covers combination pills that consist of synthetic estrogen and progesterone. The combined pill wasn’t included in the 2021 announcement, due to risks associated with the contraception to smokers aged over 35 years.
Making the pill available to purchase over the counter (OTC) at pharmacies is expected to improve access to contraception for women who struggle to obtain it through traditional avenues, such as their GP or sexual health clinics.
According to Ben Morris, a pharmacist who took part in a pilot of the scheme, anecdotal feedback has been “overwhelmingly positive”.
In the announcement accompanying the service, Morris highlighted the speed of the service, saying: “Even with the combined pill, where we need to take blood pressure, height, and weight, it’s quick, including when people first register. When it’s progesterone only, where we don’t have to do the tests like with the combined pill, it’s even quicker.”
Across the Atlantic, the first OTC birth control pill Opill (norgestrel) was approved by the US Food and Drug Administration in July 2023. This marked a milestone after continued calls from charities and organisations in the US to bring birth control pills out from behind the pharmacy counter.
by Jenna Philpott
Source: pharmaceutical-technology.com
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
